Sparton — Q2 FY2013 Earnings Presentation
14 slides from Sparton's earnings presentation, Feb 6, 2013
Slide 1: Fiscal 2013 Second Quarter Financial Results Conference Call
Exhibit 99.2 Fiscal 2013 Second Quarter Financial Results Conference Call February 6, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements herein constitute forward-looking statements within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. When used herein, words such as “believe,” “expect,” “anticipate,” “project,” “plan,” “estimate,” “w
Slide 3: Today's Agenda
Today’s Agenda • 2 nd Quarter Highlights st • Fiscal 2013 1 Half Financial Results • 2 nd Quarter Segmented Operating Results • Liquidity & Capital Resources • Outlook • Q&A 3
Slide 4: 2nd Quarter Highlights
nd 2 Quarter Highlights • Awarded 13 new business programs during the second quarter • Quarter end sales backlog of approximately $211.5 million, including approximately $30.5 million from the Onyx acquisition • Completed the acquisition of Onyx EMS, LLC. • Entered into a new five year banking agree
Slide 5: Consolidated Financial Results
Consolidated Financial Results st Fiscal 2013 1 Half (Reported) (Adjusted) (Adjusted) (Adjusted) (Adjusted) 6 months ended Dec. 31, 6 months ended Dec. 31, Total YoY Legacy YoY Onyx 2012 2011 2012 2011 Variance Variance Net Sales $ 114,999 $ 107,203 $ 114,999 $ 107,203 $ 7,796 $ 6,115 $ 1,681 Gross
Slide 6: Consolidated Financial Results
Consolidated Financial Results Adjusted EBITDA 6 months ended Dec. 31, YoY 2012 2011 Variance Net Income $ 5,354 $ 3,451 $ 1,903 Interest expense 254 347 93 Interest income (51) (48) 3 Provision for income taxes (531) 1,918 2,449 Depreciation and amortization 1,472 831 (641) Restructuring/impairment
Slide 7: Sales Results
Sales Results Medical SALES (with Onyx) 3 Months Ended December 31, 6 Months Ended December 31, SEGMENT 2012 % of Total 2011 % Change 2012 % of Total 2011 % Change Medical (with Onyx) $ 34,804 53% $ 28,027 24% $ 62,863 55% $ 55,487 13% Complex Systems 14,059 21% 12,549 12% 26,406 23% 25,109 5% DSS 2
Slide 8: Gross Profit Results
Gross Profit Results Medical ADJUSTED GROSS MARGIN (with Onyx) 3 Months Ended December 31, 6 Months Ended December 31, SEGMENT 2012 GP % 2011 GP % 2012 GP % 2011 GP % Medical (with Onyx) $ 4,910 14.1% $ 3,883 13.9% $ 9,104 14.5% $ 7,497 13.5% Complex Systems 1,428 10.2% 1,306 10.4% 2,524 9.6% 2,394
Slide 9: Onyx Operating Results
Onyx Operating Results ADJUSTED GROSS PROFIT For the 3 Months Ended December 31, For the 6 Months Ended December 31, 2012 2011 2012 2011 Pre Post Total Total Pre Post Total Total Acquisition Acquisition Onyx Onyx Acquisition Acquisition Onyx Onyx Gross Profit 723 301 1,024 1,796 3,094 301 3,395 3,83
Slide 10: Sales & Gross Profit Results
Sales & Gross Profit Results Complex Systems SALES 3 Months Ended December 31, 6 Months Ended December 31, SEGMENT 2012 % of Total 2011 % Change 2012 % of Total 2011 % Change Medical (with Onyx) $ 34,804 53% $ 28,027 24% $ 62,863 55% $ 55,487 13% Complex Systems 14,059 21% 12,549 12% 26,406 23% 25,1
Slide 11: Sales & Gross Profit Results
Sales & Gross Profit Results Defense & Security Systems SALES 3 Months Ended December 31, 6 Months Ended December 31, SEGMENT 2012 % of Total 2011 % Change 2012 % of Total 2011 % Change Medical (with Onyx) $ 34,804 53% $ 28,027 24% $ 62,863 55% $ 55,487 13% Complex Systems 14,059 21% 12,549 12% 26,4
Slide 12: Liquidity & Capital Resources
Liquidity & Capital Resources 50,000 0.45 Cash Availability 0.42 ($ in '000) Dec-11 Mar-12 Jun-12 Sep-12 Dec-12 0.4 Cash and equivalents 30,610 26,682 46,950 43,096 6,066 LOC Availability 17,290 16,469 16,277 16,012 51,000 0.35 Total 47,900 43,151 63,227 59,108 57,066 0.3 0.25 Debt 25,000 22,959 ($
Slide 13: Fiscal 2013 Outlook
Fiscal 2013 Outlook • Implementation of the strategic growth plan – Continue to gain traction on a nationally focused direct selling effort – Further leverage Viet Nam as a low cost country alternative and in-region provider – Maintain our level of investment in internal research & development to co
Slide 14: Q&A
LA) (iy) Sparton Q&A 14